EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 265 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... March 24, 2025 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 This Common Antibiotic May Help Support Immune System in Cancer Patients... December 12, 2019 Breast Cancer Patient Credits Persistent Commercial Messaging for Saving Her Life June 9, 2020 Load more HOT NEWS Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... A radical project: video game design meets cancer research Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer Bjorn Saven: “By supporting early career researchers to do their jobs...
